Rapport Therapeutics, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rapport Therapeutics, Inc. Common Stock generated cash of -$27,181,000, which is less than the previous year. Cash used in financing activities reached the amount of $145,136,000 last year. Net change in cash is therefore $39,095,000.
Cash Flow
| 2022 | -3.24M | -5.28M | 39.68M |
|---|---|---|---|
| 2023 | -27.18M | -78.86M | 145.13M |
RAPP Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 31.15M | 0 |
Operating activities | ||
Net income | -34.78M | -10.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 112K | 15K |
Stock-based compensation expense | 3.52M | 0 |
| Deferred income tax benefit | 3.52M | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 856K | 0 |
Cash generated by operating activities | -27.18M | -3.24M |
Investing activities | ||
Purchases Of Investments | -77.22M | 0 |
Investments In Property Plant And Equipment | -1.63M | -284K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -78.86M | -5.28M |
Financing activities | ||
Common Stock Issued | 54K | 31.78M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | -4K | 0 |
Repayments of term debt | 0 | 7.89M |
Cash used in financing activities | 145.13M | 39.68M |
Net Change In Cash | 39.09M | 31.15M |
Cash at end of period | 70.25M | 31.15M |